---
schema_version: "secwatch.filing_event.v1"
accession: "0000929638-25-002927"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:08:19.253956+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents Q2 revenue $9.6M (+9% YoY); net income $1.9M but adjusted loss widens

## Summary
- Revenue $9.6M, up 9% YoY (4% constant currency); Germany sales up 22% YoY and sequentially.
- Net income $1.9M ($0.03/share) vs net loss $4.3M in Q2 2024; adjusted net loss $3.7M vs $2.8M.
- Adjusted EBITDA loss $2.6M vs $2.2M in Q2 2024; cash $11.7M at quarter end.
- FDA appeal for DrugSorb-ATR held in July; administrative review expected by end of August 2025.
- Health Canada reconsideration filed; will proceed after FDA decision.

## SEC filing metadata
- accession: 0000929638-25-002927
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000092963825002927/0000929638-25-002927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000092963825002927/a8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000929638-25-002927
- JSON: https://secwatch.observer/filing/0000929638-25-002927.json
- Plain text: https://secwatch.observer/filing/0000929638-25-002927.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.